Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
-
Aziyo Biologics (AZYO) Announces Proposed Public Offering of Common Stock
-
Aziyo Biologics, Inc. Announces Proposed Public Offering of Common Stock
-
Cantor Fitzgerald Upgrades SoundHound AI Inc. (SOUN) to Overweight
-
EF Hutton Expands Healthcare Franchise with Appointments of Veteran Equity Research Analysts
-
EF Hutton Expands Healthcare Franchise with Appointments of Veteran Equity Research Analysts
-
EF Hutton Expands Healthcare Franchise with Appointments of Veteran Equity Research Analysts
-
Alaunos Therapeutics (TCRT) Prices Public Offering of Common Stock for Gross Proceeds of Approximately $15.7 Million
-
Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock
-
Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
-
Alaunos Therapeutics (TCRT) Announces Proposed Public Offering of Common Stock
-
Alaunos Therapeutics Announces Proposed Public Offering of Common Stock
-
Form NPORT-P CANTOR FITZGERALD SUSTAI For: Sep 30
-
Form APP NTC CANTOR FITZGERALD SUSTAI
-
Cantor Fitzgerald Downgrades Opiant Pharma (OPNT) to Neutral on Acqusition
-
Redhill Biopharma (RDHL) PT Lowered to $1 at Cantor Fitzgerald
-
Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
-
Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
-
OcuTerra to Participate in Upcoming Investor Conferences
-
Aziyo Biologics to Participate in Upcoming Investor Conferences
-
Form 8-K Cantor Fitzgerald Income For: Nov 16
-
Form N-23C3A CANTOR FITZGERALD SUSTAI For: Nov 18
-
Companies with NDRs 11/18
-
Cantor Fitzgerald Starts Precigen Inc. (PGEN) at Overweight, PT $7
-
RAPT Therapeutics (RAPT) Prices 4.05M Share Offering at $18.50/sh
-
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
-
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
-
Today's most important initiations
-
RAPT Therapeutics (RAPT) Announces Proposed $75M Stock Offering
-
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
-
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
-
Companies with NDRs 11/17
-
Ardelyx (ARDX) Kept at Neutral by Cantor Fitzgerald, "Need More Commercial Visibility"
-
Cantor Fitzgerald Starts Kempharm (KMPH) at Overweight
-
Cantor Fitzgerald Starts Theratechnologies Inc. (THTX) at Overweight
-
Form 424B3 Cantor Fitzgerald Income
-
Form SC 13G UTA Acquisition Corp Filed by: CANTOR FITZGERALD SECURITIES
-
Form SC 13D/A BGC Partners, Inc. Filed by: CANTOR FITZGERALD, L. P.
-
BGC Partners (BGCP) Announces Corporate Conversion Agreement, New Company Name "BGC Group" And New Ticker Symbol "BGC" In Connection With Its Conversion Into a Corporate Structure
-
BGC Partners Announces Corporate Conversion Agreement, New Company Name "BGC Group" And New Ticker Symbol "BGC" In Connection With Its Conversion Into a Corporate Structure
-
Companies with NDRs 11/16
-
UPDATE: Cantor Fitzgerald Downgrades NexImmune Inc (NEXI) to Neutral
-
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
-
Cognition Therapeutics Announces Closing of Public Offering
-
Electra Closes US$5.5 Million Public Equity Offering
-
Cognition Therapeutics Announces Closing of Public Offering
-
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
-
Form 13F-NT Cantor Fitzgerald Europe For: Sep 30
-
Form 13F-NT CANTOR FITZGERALD & CO. For: Sep 30
-
Form 13F-NT CANTOR FITZGERALD INVEST For: Sep 30

